ABBV34 Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$54.15 |
| 52 Week High | US$57.77 |
| 52 Week Low | US$39.68 |
| Beta | 0.56 |
| 1 Month Change | -3.68% |
| 3 Month Change | 7.02% |
| 1 Year Change | 6.01% |
| 3 Year Change | 44.16% |
| 5 Year Change | 182.84% |
| Change since IPO | 301.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABBV34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0.8% | -4.0% | -2.8% |
| 1Y | 6.0% | -8.0% | 12.4% |
Return vs Industry: ABBV34 exceeded the BR Biotechs industry which returned -8% over the past year.
Return vs Market: ABBV34 underperformed the BR Market which returned 12.4% over the past year.
Price Volatility
| ABBV34 volatility | |
|---|---|
| ABBV34 Average Weekly Movement | 3.2% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in BR Market | 8.5% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: ABBV34 has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV34's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 50,000 | Rick Gonzalez | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
| ABBV34 fundamental statistics | |
|---|---|
| Market cap | R$1.53t |
| Earnings (TTM) | R$25.31b |
| Revenue (TTM) | R$285.20b |
60.5x
P/E Ratio5.4x
P/S RatioIs ABBV34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABBV34 income statement (TTM) | |
|---|---|
| Revenue | US$54.32b |
| Cost of Revenue | US$16.73b |
| Gross Profit | US$37.59b |
| Other Expenses | US$32.77b |
| Earnings | US$4.82b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.72 |
| Gross Margin | 69.21% |
| Net Profit Margin | 8.87% |
| Debt/Equity Ratio | 573.6% |
How did ABBV34 perform over the long term?
See historical performance and comparison